DBPR108 is an orally active, dipeptide-based DPP4 inhibitor with an IC50 of 15 nM, demonstrating high selectivity as it does not inhibit DPP8 or DPP9. This compound is a valuable research tool for investigating DPP4 function in metabolic diseases, including diabetes, in both in vitro enzymatic assays and in vivo pharmacological studies.
